Beyond cardiovascular medicine: potential future uses of icosapent ethyl - Sorbonne Université
Article Dans Une Revue European Heart Journal Supplements Année : 2020

Beyond cardiovascular medicine: potential future uses of icosapent ethyl

Résumé

The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being actively explored in clinical studies. These areas of investigation include cancer, inflammatory bowel disease, infections, Alzheimer's disease, dementia, and depression. The next decade promises to deepen our understanding of the beneficial effects that EPA may offer beyond cardiovascular risk reduction.
Fichier principal
Vignette du fichier
suaa119.pdf (457.16 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03145015 , version 1 (18-02-2021)

Identifiants

Citer

Carol van Hulle, Deepak Bhatt, Mark A Hull, Mingyang Song, Cindy Carlsson, et al.. Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements, 2020, 22 (Supplement_J), pp.J54-J64. ⟨10.1093/eurheartj/suaa119⟩. ⟨hal-03145015⟩
16 Consultations
56 Téléchargements

Altmetric

Partager

More